Skip to content

Serotonin research published in 2019

Page 2 of 3: studies 21 to 40 of 44, newest first. Back to the serotonin overview

Studies

Para-Halogenation Affects Monoamine Transporter Inhibition Properties and Hepatocellular Toxicity of Amphetamines and Methcathinones

Frontiers in Pharmacology April 24, 2019 Dino Luethi, Melanie Walter, Xun Zhou et al. 33 citations

Halogenated derivatives of amphetamine-type stimulants are appearing on the drug market, often with altered pharmacological profile and sometimes different legal status compared to the non-halogenated substances. The aim of the present study was to investigate the pharmacological profile and hepatocellular toxicity of para-halogenated amphetamines and cathinones. The potential of amphetamine,...

DOI: 10.3389/fphar.2019.00438 (opens in new tab) Serotonin Pharmacology Amphetamine Toxicity +5

Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats

Neurotoxicity Research April 15, 2019 Monika Herian, Adam Wojtas, Katarzyna Kamińska et al. 44 citations

NBOMes are N-benzylmethoxy derivatives of the 2C family hallucinogens. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe) is one of the commonly used illicit drugs. It exhibits high binding affinity for 5-HT 2A/C and 5-HT 1A serotonin receptors. Activation of 5-HT 2A receptor induces head-twitch response (HTR) in rodents, a behavioral marker of hallucinogen effect in humans....

Conformational dynamics of the human serotonin transporter during substrate and drug binding.

Nature Communications April 11, 2019 Ingvar R Möller, Marika Slivacka, Anne Kathrine Nielsen et al. 92 citations

The serotonin transporter (SERT), a member of the neurotransmitter:sodium symporter family, is responsible for termination of serotonergic signaling by re-uptake of serotonin (5-HT) into the presynaptic neuron. Its key role in synaptic transmission makes it a major drug target, e.g. for the treatment of depression, anxiety and post-traumatic stress. Here, we apply hydrogen-deuterium exchange...

DOI: 10.1038/s41467-019-09675-z (opens in new tab) Full text (opens in new tab) Serotonin transporter Drug action Mass spectrometry

An investigation into serotonergic and environmental interventions against depression in a simulated delayed reward paradigm

bioRxiv Preprint Server April 4, 2019 Bernd Porr, Alex Trew, Alice Miller 1 citation preprint

The disruption of the serotonergic (5HT) system has been implicated in causing major depression and the standard view is that a lack of serotonin is to blame for the resulting symptoms. Consequently, pharmacological interventions aim to increase serotonin concentration in its target areas or stimulating excitatory 5HT receptors. A standard approach is to use serotonin reuptake inhibitors...

Receptor-Enriched Analysis of functional connectivity by targets (REACT): A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA

Neuroimage April 4, 2019 Ottavia Dipasquale, Pierluigi Selvaggi, Mattia Veronese et al. 79 citations

One of the main limitations of pharmacological fMRI is its inability to provide a molecular insight into the main effect of compounds, leaving an open question about the relationship between drug effects and haemodynamic response. The aim of this study is to investigate the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on functional connectivity (FC) using a novel multimodal method...

Investigating the Role of Serotonin Transporter, Plasma Membrane Monoamine Transporter, and Organic Cation Transporter 3 in the Antidepressant‐like Effects of Ketamine

The FASEB Journal April 1, 2019 Melodi Ann Bowman, Melissa Vitela, W. Anthony Owens et al.

Twenty percent of adults are diagnosed with major depressive disorder, which is typically treated with selective serotonin reuptake inhibitors (SSRIs). However, SSRIs take approximately six weeks to produce therapeutic effects. Recently, low doses of ketamine, a noncompetitive N‐methyl‐ D‐aspartate (NMDA) receptor antagonist, have been shown to produce rapid and long‐lasting antidepressant...

Sustained Activation of Postsynaptic 5-HT2A Receptors Gates Plasticity at Prefrontal Cortex Synapses.

Cerebral Cortex April 1, 2019 Coralie Berthoux, Alexander Barre, Joël Bockaert et al.

The prefrontal cortex (PFC) plays a key role in many high-level cognitive processes. It is densely innervated by serotonergic neurons originating from the dorsal and median raphe nuclei, which profoundly influence PFC activity. Among the 5-HT receptors abundantly expressed in PFC, 5-HT2A receptors located in dendrites of layer V pyramidal neurons control neuronal excitability and mediate the...

Elucidating Anti‐Inflammatory Signaling Paradigm at the 5‐HT 2A Receptor

The FASEB Journal April 1, 2019 Gerald Billac, Charles D. Nichols 1 citation

Given the recent resurgence of clinical interest in the application of classical serotonergic psychedelics as treatment for various disease states, a comprehensive analysis of the structure‐activity relationship (SAR) is necessary to fully understand the differential expression of behavioral and physiological effects elicited by these compounds. While the field is mostly focused on action...

Serotonin 2A receptors are a stress response system: implications for post-traumatic stress disorder.

Behavioural Pharmacology April 1, 2019 Kevin Sean Murnane 84 citations

Serotonin, one of the first neurotransmitters to be identified, is an evolutionarily old molecule that is highly conserved across the animal kingdom, and widely used throughout the brain. Despite this, ascribing a specific set of functions to brain serotonin and its receptors has been difficult and controversial. The 2A subtype of serotonin receptors (5-HT2A receptor) is the major excitatory...

The novel methoxetamine analogs N-ethylnorketamine hydrochloride (NENK), 2-MeO-N-ethylketamine hydrochloride (2-MeO-NEK), and 4-MeO-N-ethylketamine hydrochloride (4-MeO-NEK) elicit rapid antidepressant effects via activation of AMPA and 5-HT2 receptors

Psychopharmacology March 19, 2019 L. Sayson, Chrislean Jun Botanas, Raly James Perez Custodio et al.

RationaleDepressive syndrome or depression is a debilitating brain disorder affecting numerous people worldwide. Although readily available, current antidepressants have low remission rates and late onset times. Recently, N-methyl-D-aspartate (NMDA) receptor antagonists, like ketamine and methoxetamine (MXE), were found to elicit rapid antidepressant effects. As the search for...

Correction: Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

Neuropsychopharmacology March 8, 2019 M. Madsen, Patrick M. Fisher, Daniel Burmester et al. 21 citations correction

The original version of this article contained an error in the labelling of Figures 2 and 3. While the captions and figures themselves are correct, in order to correspond with the in-text references, they have now been re-numbered in both the PDF and HTML versions of the article.

Serotonin syndrome unmasking thyrotoxicosis.

BMJ Case Reports March 7, 2019 Geoffrey Peter Ronan, Nicola Ronan, Siobhan Mcgettigan et al. 4 citations

A 26-year-old cachectic man presented with an altered mental status. He was agitated, tremulous, hyperthermic and diaphoretic with largely dilated pupils. Collateral history revealed acute ingestion of 3,4-methylenedioxymethamphetamine on a background of chronic drug abuse. His condition deteriorated requiring sedation and intubation with transfer to the intensive care unit. A diagnosis of...

DOI: 10.1136/bcr-2018-228404 (opens in new tab) Full text (opens in new tab) Delirium Endocrine system Metabolic disorders Thyroid disease +1

Autophagy inhibition plays a protective role against 3, 4‐methylenedioxymethamphetamine (MDMA)‐induced loss of serotonin transporters and depressive‐like behaviors in rats

Pharmacological Research February 28, 2019 Jui-Hu Shih, Chuang-Hsin Chiu, Kuo-Hsing Ma et al.

Graphical abstract Figure. No Caption available. Abstract The 3,4‐methylenedioxymethamphetamine (MDMA) is a popular recreational drug, which ultimately leads to serotonergic (5‐HT) neurotoxicity and psychiatric disorders. Previous in vitro studies have consistently demonstrated that MDMA provokes autophagic activation, as well as damage of 5‐HT axons and nerve fibers. So far, whether autophagy,...

Aromatic Bromination Abolishes the Psychomotor Features and Pro-social Responses of MDMA ("Ecstasy") in Rats and Preserves Affinity for the Serotonin Transporter (SERT).

Frontiers in Pharmacology February 28, 2019 Patricio Sáez-briones, Vicente Castro-Castillo, Gabriela Díaz-véliz et al. 4 citations

The entactogen MDMA (3,4-methylenedioxy-methamphetamine, “Ecstasy”) exerts its psychotropic effects acting primarily as a substrate of the serotonin transporter (SERT) to induce a non-exocytotic release of serotonin. Nevertheless, the roles of specific positions of the aromatic ring of MDMA associated with the modulation of typical entactogenic effects, using analogs derived from the MDMA...

Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.

Journal of Psychopharmacology February 28, 2019 David Erritzøe, James Smith, Patrick M. Fisher et al. 95 citations

Background: Recent studies have suggested therapeutic benefits of psychedelics for a variety of mental health conditions. The understanding of how single psychedelic administrations can induce long-lasting effects are, in large, still lacking. However, recent studies in both healthy and clinical populations suggest a role for personality changes. Aim: To test support for some of these plausible...

DOI: 10.1177/0269881119827891 (opens in new tab) Psychedelics Recreational psychedelic experiences Recreational use Personality openness +6

Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen

Psychopharmacology February 14, 2019 Adam L. Halberstadt, Jochem V. F. Zee, Muhammad Chatha et al. 21 citations

Background There is evidence that mGlu2/3 receptors regulate 5-HT_2A signaling, interactions that have been theorized to play a role in the antipsychotic-like effects of mGlu2/3 agonists as well as the hallucinogenic effects of 5-HT_2A agonists. One approach to unraveling this interaction is through the chronic administration of agonists at the two receptors, which should influence the...

5-Methoxy-α-methyltryptamine (5-MeO-AMT), a tryptamine derivative, induces head-twitch responses in mice through the activation of serotonin receptor 2a in the prefrontal cortex.

Behavioural Brain Research February 1, 2019 Arvie Abiero, Chrislean Jun Botanas, Leandro Val Sayson et al. 17 citations

5-Methoxy-α-methyltryptamine (5-MeO-AMT) is a tryptamine derivative that is used recreationally because of its reported hallucinogenic and mood elevating effects. Studies suggest that the psychopharmacological effects of tryptamines involve serotonin receptor 2a (5-HTR2a) activation in the brain. The head-twitch response (HTR) is widely used as a behavioral correlate for assessing 5-HTR2a...

DOI: 10.1016/j.bbr.2018.07.020 (opens in new tab) Full text (opens in new tab) 5-methoxy-a-methyltryptamine Conditioned place preference Head-twitch response Self-administration +1

Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels

Neuropsychopharmacology January 26, 2019 M. Madsen, Patrick M. Fisher, Daniel Burmester et al. 505 citations

The main psychedelic component of magic mushrooms is psilocybin, which shows promise as a treatment for depression and other mental disorders. Psychedelic effects are believed to emerge through stimulation of serotonin 2A receptors (5-HT2ARs) by psilocybin's active metabolite, psilocin. We here report for the first time the relationship between intensity of psychedelic effects, cerebral 5-HT2AR...

Serotonergic Psychedelics LSD & Psilocybin Increase the Fractal Dimension of Cortical Brain Activity in Spatial and Temporal Domains

bioRxiv (Cold Spring Harbor Laboratory) January 11, 2019 Tf. Varley, Robin Carhart-Harris, Leor Roseman et al. 8 citations preprint

Abstract Psychedelic drugs, such as psilocybin and LSD, represent unique tools for researchers in-vestigating the neural origins of consciousness. Currently, the most compelling theories of how psychedelics exert their effects is by increasing the complexity of brain activity and moving the system towards a critical point between order and disorder, creating more dynamic and complex patterns of...

Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study

Human Brain Mapping January 11, 2019 Dea Siggaard Stenbæk, Sara Kristiansen, Daniel Burmester et al. 11 citations

Abstract Recent research found lasting increases in personality trait Openness in healthy individuals and patients after administration of the serotonin 2A receptor (5‐HT 2A R) agonist psilocybin. However, no studies have investigated whether 5‐HT 2A R availability as imaged using positron emission tomography (PET) is associated with this trait. In 159 healthy individuals (53 females), the...

DOI: 10.1002/hbm.24511 (opens in new tab) Serotonin Positron emission tomography Trait Openness to experience +1